[go: up one dir, main page]

NO178401C - Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-heteroaryl-triazolo-[1,5-aÅ[1,3,5Åtriaziner og -pyrazolo[2,3-aÅ[1,3,5Åtriaziner og nye mellomprodukter for fremstilling derav - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-heteroaryl-triazolo-[1,5-aÅ[1,3,5Åtriaziner og -pyrazolo[2,3-aÅ[1,3,5Åtriaziner og nye mellomprodukter for fremstilling derav

Info

Publication number
NO178401C
NO178401C NO912051A NO912051A NO178401C NO 178401 C NO178401 C NO 178401C NO 912051 A NO912051 A NO 912051A NO 912051 A NO912051 A NO 912051A NO 178401 C NO178401 C NO 178401C
Authority
NO
Norway
Prior art keywords
triazines
preparation
triazolo
pyrazolo
heteroaryl
Prior art date
Application number
NO912051A
Other languages
English (en)
Norwegian (no)
Other versions
NO912051D0 (no
NO912051L (no
NO178401B (no
Inventor
Peter William Rodney Caulkett
Geraint Jones
Michael George Collis
Simon Martin Poucher
Original Assignee
Zeneca Ltd
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909011913A external-priority patent/GB9011913D0/en
Priority claimed from GB909011914A external-priority patent/GB9011914D0/en
Priority claimed from GB919101379A external-priority patent/GB9101379D0/en
Priority claimed from GB919101380A external-priority patent/GB9101380D0/en
Priority claimed from GB919104125A external-priority patent/GB9104125D0/en
Application filed by Zeneca Ltd, Ici Plc filed Critical Zeneca Ltd
Publication of NO912051D0 publication Critical patent/NO912051D0/no
Publication of NO912051L publication Critical patent/NO912051L/no
Publication of NO178401B publication Critical patent/NO178401B/no
Publication of NO178401C publication Critical patent/NO178401C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO912051A 1990-05-29 1991-05-28 Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-heteroaryl-triazolo-[1,5-aÅ[1,3,5Åtriaziner og -pyrazolo[2,3-aÅ[1,3,5Åtriaziner og nye mellomprodukter for fremstilling derav NO178401C (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909011913A GB9011913D0 (en) 1990-05-29 1990-05-29 Azole derivatives
GB909011914A GB9011914D0 (en) 1990-05-29 1990-05-29 Heterocyclic compounds
GB919101379A GB9101379D0 (en) 1991-01-22 1991-01-22 Heterocyclic compounds
GB919101380A GB9101380D0 (en) 1991-01-22 1991-01-22 Azole derivatives
GB919104125A GB9104125D0 (en) 1991-02-27 1991-02-27 Azole derivatives

Publications (4)

Publication Number Publication Date
NO912051D0 NO912051D0 (no) 1991-05-28
NO912051L NO912051L (no) 1991-12-02
NO178401B NO178401B (no) 1995-12-11
NO178401C true NO178401C (no) 1996-03-20

Family

ID=27516979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO912051A NO178401C (no) 1990-05-29 1991-05-28 Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-heteroaryl-triazolo-[1,5-aÅ[1,3,5Åtriaziner og -pyrazolo[2,3-aÅ[1,3,5Åtriaziner og nye mellomprodukter for fremstilling derav

Country Status (20)

Country Link
US (1) US5270311A (fr)
EP (1) EP0459702A1 (fr)
JP (1) JP2504879B2 (fr)
KR (1) KR910020012A (fr)
CN (1) CN1056879A (fr)
AP (1) AP248A (fr)
AU (1) AU642494B2 (fr)
CA (1) CA2043424A1 (fr)
CS (1) CS159591A3 (fr)
FI (1) FI912563A (fr)
GB (1) GB2244487B (fr)
HU (1) HUT61311A (fr)
IE (1) IE911818A1 (fr)
IL (1) IL98316A (fr)
NO (1) NO178401C (fr)
NZ (1) NZ238288A (fr)
OA (1) OA09358A (fr)
PT (1) PT97776A (fr)
RO (1) RO109542B1 (fr)
YU (1) YU47812B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) * 1992-12-22 1993-02-17 Ici Plc Azole derivatives
EP0459702A1 (fr) * 1990-05-29 1991-12-04 Zeneca Limited Dérivés d'azoles
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
GB9124968D0 (en) * 1991-11-25 1992-01-22 Ici Plc Chemical process
GB9125002D0 (en) * 1991-11-25 1992-01-22 Ici Plc Azole derivatives
GB9125001D0 (en) * 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
DE69428977T2 (de) * 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
US5789407A (en) * 1993-09-06 1998-08-04 Kyowa Hakko Kogyo Co., Ltd. Method of treating depression with certain triazine derivatives
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
NZ510629A (en) * 1998-09-22 2003-04-29 Kyowa Hakko Kogyo Kk [1,2,4]Triazolo[1,5-c]pyrimidine derivatives and pharmaceutical use as adenosine A2A receptor antagonists
EP1544200A1 (fr) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. D riv de 1,2,4]-triazolo 1,5]pyrimidine
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP1633756B1 (fr) 2003-04-09 2008-12-24 Biogen Idec MA Inc. Antagonistes de recepteur d'adenosine a2a
EP1615930A2 (fr) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines et pyrazolotriazines et leurs procedes de fabrication et d'utilisation
EP1615931A1 (fr) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
WO2004092172A2 (fr) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines et pyrazolo[1,5-c]pyrimidines et procedes de preparation et d'utilisation de celles-ci
WO2004110454A1 (fr) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
EP1856053A1 (fr) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Derives de cinnamide et d'hydrocinnamide presentant une activite inhibitrice de raf-kinase
EP2920417A1 (fr) 2012-12-06 2015-09-23 Siemens Aktiengesellschaft Système et procédé permettant de faire entrer de la chaleur dans une formation géologique par induction électromagnétique
CN106916073A (zh) * 2017-01-20 2017-07-04 上海巧坤化工科技有限公司 一种大麦芽碱盐酸盐的合成方法
WO2019154294A1 (fr) * 2018-02-06 2019-08-15 江苏恒瑞医药股份有限公司 Dérivé de pyrazolo[1,5-a][1,3,5]triazine-2-amine, son procédé de préparation et son utilisation médicale
EP3814355A4 (fr) * 2018-06-26 2022-06-08 Zhejiang Vimgreen Pharmaceuticals, Ltd Dérivés de triazolotriazine en tant qu'antagonistes du récepteur a2a
JP7197206B2 (ja) * 2018-06-26 2022-12-27 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体
BE1026602B1 (fr) 2018-09-27 2020-06-18 Iteos Therapeutics S A Inhibiteurs d’a2a ne penetrant pas dans le cerveau et methodes d’utilisation dans le traitement de cancers
CN111205291B (zh) * 2018-11-22 2022-08-23 上海科技大学 三唑并环类化合物、其制备方法、中间体和应用
CN112500416B (zh) * 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
US20230048888A1 (en) * 2019-12-26 2023-02-16 Zhejiang Vimgreen Pharmaceuticals, Ltd. Use of triazolotriazine derivative in treatment of diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846423A (en) * 1972-06-08 1974-11-05 Icn Pharmaceuticals Pyrazolo (1,5a) 1,3,5-triazines
ZA743316B (en) * 1973-05-22 1976-01-28 Sandoz Ltd Improvements in or relating to organic compounds
US3995039A (en) * 1975-05-27 1976-11-30 Merck & Co., Inc. Pyrazolo [1,5-a] [1,3,5] triazines
GB1579932A (en) * 1976-05-12 1980-11-26 Ici Ltd Herbicidal triazolotriazines
GB2016002B (en) * 1978-01-09 1982-05-06 Aron Sa Amino derivatives of pyrazolo(1,5-a)s triazine
AU2192683A (en) * 1982-12-30 1984-07-05 Biomeasure Incorporated Pyrazolo(1,5-alpha)-1,3,5-triazines
CA1267143A (fr) * 1985-06-06 1990-03-27 Sun H. Kim Derives de 7-phenylpyrazole[1,5-a]-1,3,5-triazine, agents anti-arthrite
DE3677445D1 (de) * 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
WO1988002370A1 (fr) * 1986-09-30 1988-04-07 Ciba-Geigy Ag Triazolo-1,5-c pyrimidines-1,2,4 substituees en position 2 et accolees en face e
US4824834A (en) * 1986-10-31 1989-04-25 Otsuka Pharmaceutical Company, Limited Pyrazolotriazine compounds
US4734413A (en) * 1987-03-02 1988-03-29 Riker Laboratories, Inc. Substituted 1,2,4-triazolo[1,5-A]triazines as bronchodilators
DE3885357T2 (de) * 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US4970142A (en) * 1989-02-16 1990-11-13 Konica Corporation Silver halide photographic light-sensitive material containing cyan coupler
EP0459702A1 (fr) * 1990-05-29 1991-12-04 Zeneca Limited Dérivés d'azoles

Also Published As

Publication number Publication date
CA2043424A1 (fr) 1991-11-30
YU47812B (sr) 1996-01-09
AU7734891A (en) 1991-12-05
EP0459702A1 (fr) 1991-12-04
AP248A (en) 1993-03-16
NO912051D0 (no) 1991-05-28
PT97776A (pt) 1992-03-31
GB2244487A (en) 1991-12-04
GB2244487B (en) 1994-02-02
KR910020012A (ko) 1991-12-19
JPH0597855A (ja) 1993-04-20
FI912563A (fi) 1991-11-30
CN1056879A (zh) 1991-12-11
YU94791A (sh) 1994-06-24
NO912051L (no) 1991-12-02
AP9100266A0 (en) 1991-07-31
RO109542B1 (ro) 1995-03-30
IE911818A1 (en) 1991-12-04
OA09358A (fr) 1992-09-15
NZ238288A (en) 1993-07-27
IL98316A (en) 1995-05-26
AU642494B2 (en) 1993-10-21
HUT61311A (en) 1992-12-28
JP2504879B2 (ja) 1996-06-05
NO178401B (no) 1995-12-11
GB9111132D0 (en) 1991-07-17
CS159591A3 (en) 1992-01-15
US5270311A (en) 1993-12-14
FI912563A0 (fi) 1991-05-28
HU911789D0 (en) 1991-12-30
IL98316A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
NO178401C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-heteroaryl-triazolo-[1,5-aÅ[1,3,5Åtriaziner og -pyrazolo[2,3-aÅ[1,3,5Åtriaziner og nye mellomprodukter for fremstilling derav
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
FI890282A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI913477A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten imidatsoli-fenyyli-imidatso/1,2-a/pyridiini- ja imidatsoli-fenyyli-imidatso/1,2-a/pyrimidiinijohdannaisten valmistamiseksi
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
NO175978C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive bis-aza-bicykliske forbindelser
NO175100C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive 4(3H)-pteridinoner
NO177057C (no) Fremgangsmåte for fremstilling av pyrrolopyrimidiner og mellomprodukter derav
NO176275C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazinonderivater
NO175873C (no) Mikrobiell fremgangsmåte for fremstilling av immunhemmende antibiotika
FI880467A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 3,4-dihydro-2H-bentsopyraanien valmistamiseksi
IL98126A0 (en) Process for the preparation of dialkyl pyridine-2,3-dicarboxylate and derivatives thereof from dialkyl dichlorosuccinate
FI900897A0 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroimidatso/4,5,1-jk//1,4/bentsodiatsepiini-2(1H)-tionijohdannaisten valmistamiseksi
NO175976C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
FI92205C (fi) Menetelmä terapeuttisesti käyttökelpoisten N-pyrrolo- ja pyrido /3,2,1,-j k/ /1,4/ bentsodiatsepinyyli-N'-aryyliurea ja tioureajohdannaisten valmistamiseksi
NO177712C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk virksomme alkylfosfonoseriner
EG19767A (en) Process for preparing of substituted 1,2,4- triazinediones intermediates therefor and their use
AU7291891A (en) Process for the isolation and expression of the human ciliary neuronotrophic factor by recombinant dna technology
NO179101C (no) Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol
FI880282A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3-aryyli-5-alkyylisulfinyyli- ja sulfonyyli-4H-1,2,4-triatsolien valmistamiseksi
NO177673C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive N7-substituerte mitomycinderivater
NO176180C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-karbonyl-substituerte N,N-di(trimetoksybenzoyl) piperanziner
FI93216C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
FI943833A0 (fi) Menetelmä 2,3,5,6-tetraklooripyridiinin valmistamiseksi